Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 2/20 | 0.53 |
| ▸ | TERT | O14746 | 1/20 | 0.53 |
| ▸ | PYGM | P11217 | 4/20 | 0.50 |
| ▸ | PYGL | P06737 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109064 | 0.89 | TOP1 (0.68) | TOP1TERTPYGMPYGLSMN1; SMN2 | |
| SCHEMBL2605620 | 0.75 | TOP1 (0.76) | TOP1PYGMPYGLSMN1; SMN2CYP1A2 | |
| SCHEMBL5459248 | 0.74 | TERT (0.46) | TOP1TERTPYGMPYGL | |
| SCHEMBL108233 | 0.70 | TOP1 (0.67) | TOP1PYGMPYGLSMN1; SMN2LMNA | |
| SCHEMBL12190105 | 0.70 | SMN1; SMN2 (0.60) | PYGMPYGLSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL27716603 | 0.70 | PYGM (0.58) | PYGMPYGLSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL27716628 | 0.69 | PYGM (0.77) | PYGMPYGLSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL108264 | 0.69 | NPC1 (0.74) | SMN1; SMN2LMNAMAPT | |
| SCHEMBL27716717 | 0.69 | CACNA1H (0.60) | PYGMPYGLSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL7119403 | 0.69 | PYGM (0.76) | PYGMPYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919530-B2 | Compounds, compositions, and methods for the treatment of synucleinopathies | PROTEOTECH, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100179223-A1 | Compounds, Compositions, and Methods for the Treatment of Synucleinopathies | PROTAMED, INC. | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179223-A1 | Compounds, Compositions, and Methods for the Treatment of Synucleinopathies | SNCA, PARK7, COMT | TOP1 2527/4885TERT 1007/4885PYGM 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.